ACAD - ACADIA Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.431B

Cash

438.9M

Avg Qtr Burn

N/A

Short % of Float

10.19%

Insider Ownership

0.49%

Institutional Own.

99.56%

Qtr Updated

12/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DAYBUE™ (Trofinetide ) Details Rett syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUPLAZID® (pimavanserin) (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details Parkinson's disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACP-101 (intranasal carbetocin) Details Prader-Willi syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACP-204 Details Alzheimer's disease	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NUPLAZID® (pimavanserin) (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ACP-044 Details Pain, Post operative acute pain	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pimavanserin (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details Schizophrenia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.